
Oxford Cannabinoid Technologies reaches milestone with phase 1 trial approval for pain relief drug



NEWS RELEASE BY OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

London, UK | May 18, 2023 07:21 AM Eastern Daylight Time



Oxford Cannabinoid Technologies Holdings PLC Clarissa Sowemimo-Coker tells Proactive's Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, is a significant milestone for the company. Sowemimo-Coker said recruitment for the trial has already begun, with completion expected in the third quarter of 2023.

The drug targets chemotherapy-induced peripheral neuropathy (CIPN) and has the potential for other indications like irritable bowel syndrome (IBS) and other neuropathy. The phase 1 trial focuses on safety and will pave the way for phase 2 trials in other indications, she added.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Tags

HEALTH WELLNESS BIOTECH PHARMA CANNABIS PAIN RELIEF